Brazil poised for big pharma growth

Guess who's the new up-and-comer in pharma? Brazil. Despite a burdensome tax structure, foreign companies are investing heavily in the country, taking advantage of incentives to entry into its generics market. India's Ranbaxy, Germany's Hexal, and Canada's Apotex are among the players in manufacturing. Plus, with almost a quarter of manufacturing capacity unfilled, it's in a perfect position to ramp up for increasing demand. All told, Brazil is among seven "pharmerging" markets expected to grow 12-13 percent next year alone.

- read the story at Outsourcing Pharma

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.